Kornimate/medical-research-clean huggingface dataset:
far infrared irradiation for managing and treating multiple sclerosis (ms)

Conditions: Multiple Sclerosis

Summary: multiple sclerosis (abbreviated ms) is an autoimmune condition in which the immune system attacks the central nervous system (cns), leading to demyelination. this study will investigate the use of far infrared radiation for ms control, management and treatment.

ms a demyelinating disease, is any disease of the nervous system in which the myelin sheath of neurons is damaged. this impairs the conduction of signals in the affected nerves, causing impairment in sensation, movement, cognition, or other functions depending on which nerves are involved. ms affects the areas of the brain and spinal cord known as the white matter. white matter cells carry signals between the grey matter areas, where the processing is done, and the rest of the body. more specifically, ms destroys oligodendrocytes which are the cells responsible for creating and maintaining a fatty layer, known as the myelin sheath, which helps the neurons carry electrical signals. observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells. it is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have ms.

Eligibility criteria:
inclusion criteria: * patients with ms exclusion criteria: * none

Keywords: ms (multiple sclerosis) multiple sclerosis, acute fulminating sclerosis, disseminated
epilepsy impact scale

Conditions: Epilepsy

Summary: the investigators are developing a questionnaire that can quickly measure the impact that epilepsy has on a person's life. this questionnaire will be useful in following whether the impact of epilepsy increases, decreases or stays the same over time. the results also may point out areas that would benefit from discussion or attention in visits with your doctor.

the investigators have used a set of broad open-ended questions about the impact of epilepsy on a person's life to formulate a long list of questions to characterize the impact the seizures, medications, and comorbidities that you are having. in the future, this will be boiled down to a short list of questions.

Eligibility criteria:
inclusion criteria: 1. age 18 or more. 2. patient has had at least 1 seizure in the past 365 days. 3. patient can speak and understand english. exclusion criteria: 1. patients suspected of having one of the imitators of epilepsy, for example, syncope, sleep disorder, psychogenic nonepileptic seizures, will be excluded, even if they also have epileptic seizures. 2. patients unwilling to spend the time doing the questionnaire.

Keywords: epilepsy quality of life seizure severity antiepileptic drug side effects questionnaire patient reported outcomes
the effect of probiotics on gingivitis: part 2

Conditions: Gingivitis; Chronic

Summary: the aim of the study is to assess the effect of oral probiotics containing streptococcus salivarius m18 on gingivitis and oral hygiene in young adults.

this will be a double-blind, randomized, placebo-controlled two-arm parallel-group study of the effect of oral probiotics containing streptococcus salivarius m18 on gingivitis and oral hygiene. the groups will include young adults with gingivitis diagnosed clinically. to assess the effect of oral probiotics, the following parameters will be used: gingival health (gingival index, gi; gingival bleeding index, gbi) and oral hygiene level (the turesky modification of the quigley-hein plaque index, tmqhpi).

Eligibility criteria:
inclusion criteria: * aged between 18-25 years * permanent bite; * presence of more than 20 teeth; * absence of systemic and chronic diseases; * the diagnosis of gingivitis stated clinically. exclusion criteria: * presence of mild, moderate or severe chronic periodontitis; * refusal to sign informed consent; * taking supplements and medication containing probiotics or prebiotics 1 months before the study; * taking antibiotics (within 3 months before the study); * allergy to the components of the drugs used in the study; * presence of immunodeficiency, taking immunosuppressants. * use of other hygiene products, immunostimulants and antibacterials, probiotics, prebiotics during the study; * refusal to take a given medication; * failure to attend check-ups.
hypofractionated stereotactic radiation therapy of brain metastases: evaluation of whole-brain radiotherapy

Conditions: Brain Metastasis

Summary: the aim is to identify in patients with brain metastases the predictive factors of overall survival, survival without local recurrence and survival with progression-free brain metastases after complementary whole brain radiotherapy.


Eligibility criteria:
inclusion criteria: * patients with one to three brain metastases treated in our department with hypofractionated stereotactic radiotherapy (srt) from march 2008 to february 2013. exclusion criteria: * a patient record captured after february 2013.
randomized study of cognitive-behavioral therapy vs imipramine and their combination for panic disorder

Conditions: Panic Disorder

Summary: objectives: i. determine which treatment is most effective for patients with panic disorder: cognitive-behavioral therapy (cbt) plus imipramine (imi), cbt plus placebo, cbt alone, imi alone, or placebo alone.

protocol outline: this is a randomized, double-blind, placebo-controlled study. patients are randomized to receive one of five treatments: cognitive-behavioral therapy (cbt) alone, imipramine plus medical management (imi), cbt plus imi, pill placebo plus medical management (pla), or cbt plus pla. patients are seen by therapists for 11 sessions over 12 weeks (3 sessions during days 1-10 followed by 6 weekly sessions and 2 biweekly sessions). each cbt session lasts approximately 1 hour, each imi session lasts approximately 30 minutes, and patients in combined treatment see 2 therapists for a total of about 80 minutes. oral imi or placebo is taken daily. patients not responding to placebo or imi after the initial 12 weeks are offered alternative treatment for up to 3 months or given a referral; responders continue to be treated monthly for the next 6 months. this is followed by a washout period of 6 months, after which patients receive final assessment. all therapy and assessment sessions are video- or audiotaped. patients are interviewed by an independent evaluator at the start of treatment and 3, 9, and 15 months later, and must keep a set of weekly self-monitoring forms. in addition, patients complete rating forms and questionnaires, and undergo carbon dioxide measurement at the start of treatment and 3, 9, and 15 months later. at study conclusion, patients are told which medication they received and receive treatment recommendations.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * principal diagnosis of panic disorder with or without mild agoraphobia, confirmed using the anxiety disorders interview schedule-revised * at least one full or limited panic attack per week within 2 weeks prior to initial assessment and 2 weeks prior to treatment --prior/concurrent therapy-- * drug washout required if on anxiolytic or antidepressant medication no more than 10 benzodiazepine doses (0.5 mg alprazolam equivalent) within 2 weeks prior to treatment no more than 20 doses of benzodiazepine during baseline and acute treatment combined no more than one dose of benzodiazepine per day permitted * no concurrent competing treatment --patient characteristics-- * not pregnant negative serum pregnancy test required effective contraception required of fertile women no psychotic, bipolar, or significant medical illnesses not suicidal no significant substance abuse no prior nonresponse to either study treatment or related treatments no concurrent disability claims

Keywords: anxiety disorder disease-related problem/condition neurologic and psychiatric disorders panic disorder rare disease
guiding instillation in non muscle-invasive bladder cancer based on drug screens in patient derived organoids

Conditions: Bladder Cancer; Non-muscle Invasive

Summary: from patients with intermediate risk non-muscle invasive bladder cancer tumor (nmibc) specimens will be harvested during transurethral resection. fresh specimens will be cultured as patient derived organoids (pdo). after approx. 10 days, pdo are exposed to different drugs that are used as intravesical instillation agents in these patients (epirubicin, mitomycin, gemcitabine, docetaxel). after 2 days of exposure, pdo viability will be measured. the drug with the highest antitumor effect on pdo will be applied as weekly intravesical instillations 6 times. thereafter, patients are followed according to the standard of care.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * signed informed consent form * ecog performance status of 0 or 1 * histologically confirmed intermediate risk non muscle-invasive urothelial carcinoma of the bladder (pta low grade) patients * representative fresh tumor specimen for pdo generation and drug screen exclusion criteria: * known previous high grade and/or high risk non muscle-invasive bladder cancer * previous intravesical biological/immuno (bcg) therapy * pregnancy or nursing * evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol * severe infection within 4 weeks prior to cycle 1, day 1 * contraindication for frequent catheterization * voiding dysfunction * pregnancy or nursing * female subject of childbearing potential who is unwilling to use acceptable method(s) of effective contraception during study treatment and through 6 months after the last treatment. * male subject who is unwilling to use acceptable method of effective contraception during ip treatment and through 6 months after the last dose of ip.
soil-transmitted helminth reinfection rates after single and repeated school hygiene education

Conditions: Helminthiasis; Ascaris Infection; Trichuris Infection; Hookworm Infections; Children, Only

Summary: soil-transmitted helminth (sth) infections caused by ascaris lumbricoides, trichuris trichiura, or hookworm, affect approximately 1.5 millions individuals primarily in tropical and subtropical regions. sths infections have been associated with delay in growth and development in children. the prevalence in indonesia varied from 45% to 65%, but in poor sanitation areas the prevalence can increased to 80%. world health organization currently recommends mass treatment with benzimidazoles and health hygiene education to control the disease. in this study we evaluated the effectiveness of single and four-monthly health hygiene education to sth reinfection rates among school-aged children in mandailing natal district, north sumatera province, indonesia.

in this study we evaluate the prevalence of sth among school-aged children using kato katz examination prior to enrolment to the study. two elementary schools in mandailing natal district, north sumatera province, indonesia have been selected and received either a single or repeated health hygiene education. preliminary knowledge was also assessed using a questionnaire. infected children received treatment of albendazole 400 mg for 3 days. evaluation on reinfection status and sth knowledge is done at 4 month, 8 month and 12 months.

Eligibility criteria:
inclusion criteria: * children who are negative for sths infection on kato katz examination following 3 days treatment of albendazole exclusion criteria: * parents who refused to participate in the study * severe malnutrition * co-infected with other helminth infections

Keywords: soil-transmitted helminth school-aged children health hygiene education
safety and efficacy study of jnj-64304500 in participants with moderately to severely active crohn's disease

Conditions: Crohn Disease

Summary: the purpose of the study is to assess the safety and efficacy of jnj-64304500 in participants with moderately to severely active crohn's disease.


Eligibility criteria:
inclusion criteria: * have crohn's disease or fistulizing crohn's disease of at least 3 months' duration, with colitis, ileitis, or ileocolitis, confirmed at any time in the past by radiography, histology, and/or endoscopy * a woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin \[b-hcg\]) pregnancy test result at screening and a negative urine pregnancy test result at week 0 * adhere to the following requirements for concomitant medication for the treatment of crohn's disease, which are permitted provided that doses meeting these requirements are stable, or have been discontinued, for at least 3 weeks before baseline (week 0), unless otherwise specified: a) oral 5-aminosalicylic acid (5-asa) compounds, b) oral corticosteroids at a prednisone-equivalent dose at or below 40 milligram per day (mg/day), or 9 mg/day of budesonide, or 5 mg/day beclomethasone dipropionate, c) antibiotics being used as a primary treatment of crohn's disease, d) conventional immunomodulators (that is, azathioprine (aza), 6-mercaptopurine (6-mp), or methotrexate (mtx)): participants must have been taking them for at least 12 weeks and at a stable dose for at least 4 weeks before baseline * a participant who has had extensive colitis for greater than or equal to (\>=) 8 years, or disease limited to the left side of the colon for \>= 12 years, must either have had a colonoscopy to assess for the presence of dysplasia within 1 year before the first administration of study agent or a colonoscopy to assess for the presence of malignancy at the screening visit, with no evidence of malignancy * have active crohn's disease, defined as a baseline crohn's disease activity index (cdai) score of \>= 220 but \<= 450 exclusion criteria: * participants who have received intravenous (iv) corticosteroids less then (\<)3 weeks or have received tumor necrosis factor-alpha (tnf-alpha) antagonist biologic agents (example, monoclonal antibody \[mab\] therapies) or other agents intended to suppress or eliminate tumor necrosis factor-alpha (tnf-alpha) \<8 weeks or have received vedolizumab \<16 weeks before the first administration of study drug * woman who is pregnant or planning pregnancy or is a man who plans to father while randomized in the study or within 16 weeks after the last administration of study agent * participants with certain complications of crohn's disease that would make it hard to assess response to study drug * participants with a history of or ongoing chronic or recurrent infectious disease * has previously received a biologic agent targeting interleukin (il)-12 or il-23, including but not limited to ustekinumab or briakinumab (abt-874)
minimally invasive esophagectomy pain control trial

Conditions: Postoperative Pain, Acute; Postoperative Complications

Summary: a pilot randomized controlled trial comparing intercostal nerve blocks, cryo-ablation plus intercostal nerve blocks, and serratus plane catheter plus intercostal nerve blocks in patients undergoing esophagectomies with minimally invasive thoracic approaches.

pilot study planned to consent 30 patients in total with a projected study timeline of 2-3 years for completion. participants will be enrolled in the study and randomized in their preoperative clinic visit. on the day of surgery, they will receive the intervention they were randomized to. 10 patients will be randomized to the intercostal block group, 10 patients will be randomized to the cryo-ablation plus intercostal block group, and 10 patients will be randomized to the serratus plane catheter plus intercostal block group. they will be followed throughout their hospital stay until discharge for data collection purposes. once the patient is discharged from the hospital, post-operative follow-up in the swedish thoracic surgery clinic will be collected up to 1 year post-operatively.

Eligibility criteria:
inclusion criteria: all adult individuals who undergo an esophagectomy with an intended minimally invasive approach of the chest at swedish medical center-first hill. these approaches include: * 3-hole with r video-assisted thoracoscopic surgery (vats) * ivor lewis r vats exclusion criteria: * age \<18 * unable to consent * additional surgical procedures planned * patients with previous thoracic surgery * patient with chronic pain on a daily regimen of narcotics * non-english speaking * contraindications to neuraxial anesthesia (ongoing anticoagulation, anticipated post-operative therapeutic anticoagulation, spinal cord stimulators, anatomic abnormalities preventing epidural placement)
a retrospective analysis of percutaneous endoscopic gastrostomy experiences

Conditions: Nutrition Disorders; Gastrostomy

Summary: the application of peg in geriatric-palliative care has not been well discussed. with the development of endoscopic procedures and peg devices, we can perform this minimally invasive method more safely, even in challenging cases. we should discuss the indications of peg in the field of palliative care of geriatric patients. the presented study evaluated geriatric (\> 65-year-old) palliative care patients to whom peg applied at our institution.

palliative care is a treatment method that focuses on the patient and patient's family, aims to minimize the complaints caused by chronic diseases that cannot be treated, and increases life quality. the national institute for health and care excellence defines palliative care as; the active, holistic care of patients with an advanced progressive illness. management of pain and other symptoms and providing psychological, social, and spiritual support is paramount. anorexia, weight loss, and sarcopenia are highly visible and distressing reminders of the life-limiting disease's influence on patients who require palliative care. given this multifaceted and significant role, it is not unexpected that nutritional treatment method choices can be challenging. percutaneous endoscopic gastrostomy (peg) is a minimally-invasive endoscopic procedure that creates a passage from the patient's stomach to the abdominal wall via a feeding tube and provides a means of feeding if oral intake is not adequate. this safe and effective minimally-invasive option has been utilized in medical practice for over 40 years. peg has advantages such as being minimally invasive, causing a low rate of complications and morbidity, and providing a long-lasting and safe feeding route. it is currently the chosen procedure for medium- and long-term enteral feeding in cases who need palliative care. the application of peg in geriatric-palliative care has not been well discussed. with the development of endoscopic procedures and peg devices, we can perform this minimally invasive method more safely, even in challenging cases. we should discuss the indications of peg in the field of palliative care of geriatric patients. the presented study evaluated geriatric (\> 65-year-old) palliative care patients to whom peg applied at our institution.

Eligibility criteria:
inclusion criteria: - we retrospectively assessed the medical datum of peg applied \>65-year-old patients at our institution between december 2017 and march 2021 in our clinic. exclusion criteria: * we excluded the patients who were not treated in our palliative care center.
impact of new biomarkers on maintenance of sinus rhythm after cardioversion or ablation of atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the biorhythm study aims to investigate the utility of new biomarkers (e.g. mr proanp, st2) measured pre-procedure for the prediction of procedural success in patients with atrial fibrillation undergoing cardioversion or ablation.

this is a prospective, observational, multicentre study of patients with paroxystic or persistent atrial fibrillation scheduled to undergo cardioversion or ablation of af in routine practice. serum levels of mr proanp and st2 pre-procedure will be measured to attempt to identify a threshold that carries prognostic value for procedural success (maintenance of sinus rhythm at one year).

Eligibility criteria:
inclusion criteria: * patients with paroxystic or persistent atrial fibrillation for whom a decision to perform ablation is made. * patients with persistent atrial fibrillation for whom a decision to perform cardioversion is made. * patients with social security coverage, or beneficiary thereof. * patients who provide written informed consent. exclusion criteria: * age \ 80 years * patients with significant valvular heart disease defined as symptomatic aortic valve disease, severe aortic or mitral stenosis or tricuspid or mitral insufficiency grade 3/4 or 4/4 * patients with pulmonary arterial hypertension \>45 mmhg on echocardiography * patients with chronic respiratory disease, chronic obstructive pulmonary disease stage ii, iii or iv. * patients with a left ventricular ejection fraction \<45% * patients with recent (\<1 month) acute decompensation of heart failure * patients with recent (\<1 month) acute coronary syndrome * anemia (hemoglobin \<10 g/dl) * pregnant or lactating women * patients with anticipated poor compliance, as assessed by the study investigator * patients within the exclusion period of another clinical study * patients under legal guardianship
dextenza in pterygium surgery

Conditions: Pterygium

Summary: dextenza for the treatment of post-surgical pain and inflammation compared to standard of care topical prednisolone acetate 1% in patients who undergo pterygium surgery (excision of pterygium with conjunctival autograft)

in patients who undergo pterygium surgery, eyes will be consecutively assigned to receive either dextenza or topical prednisolone acetate 1%.15 eyes will receive a dextenza insertion into both the upper and lower puncta at the time of surgery, followed by at postoperative month 1 visit institution of topical prednisolone acetate 1% bid x 2 weeks then qd x 2 weeks then discontinued. 15 eyes will receive starting on postoperative day 1 topical prednisolone acetate 1% q2 hours x 2 weeks then qid for 2 weeks then bid for 2 weeks then qd for 2 weeks then discontinued.

Eligibility criteria:
inclusion criteria: a patient's study eye must meet the following criteria to be eligible for inclusion in the study: • age of at least 18 years with primary pterygia exclusion criteria: a patient who meets any of the following criteria will be excluded from the study: * glaucoma * ocular hypertension * prior conjunctival surgery * other uncontrolled ocular disease * ocular surgery in either eye within 3 months * use of eye drops other than postoperative medications and artificial tears